Webflow Homepage
Our Science
Veterinarians
For Canine lymphoma & Leukemia
Personalized Prediction Profile
AI-Driven Drug Response Predictions
(Flow Cytometry + PARR included)
Immunoprofile
Get definitive diagnostic support from the start
(Flow Cytometry + PARR)
Flow Cytometry
Accurately determine lymphoma or leukemia subtypes
PARR
Determine the diversity of B-cell and T-cell clones
For Canine Patients
Multidrug Sensitivity Genotyping (MDR1)
Identify MDR1 carrier status with ease
for veterinarians
Order Services via Vet Portal
Request Sample Reports
See what you will get when you order ImpriMed's services
Become an ImpriMed Provider
Participate in Our Research
Veterinary Cancer Pioneers Podcast
Contact Us
Pet Parents
LEARN
How It Works
Lymphoma 101
Blog
Content Library
Get Started
Find a Veterinary Oncologist
Talk to Your Veterinarian
Customer stories & Case Studies
ImpriMed Reviews
Discover what other pet parents are saying and how oncologists use ImpriMed's reports
Company
Company
About Us
Careers
Press
Contact Us
Contact Us
Other Links
ImpriMed Korea
Pricing
Find a Vet
Get Started
Press
Newsroom
Contact
press@imprimedicine.com
Follow
Download
Press Kit
Featured articles
USA Today
ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment
Read More →
International Business Times
ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization
Read More →
MedCity News
Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator
Read More →
Latest Stories
Button Text
In the News
Button Text
Presentations
Button Text
Press Releases
Button Text
Scientific Publications
Button Text
Video/Podcast Interviews
In the News
Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator
MedCity News
Learn More →
In the News
Be sure to improve your cancer treatment outcomes
Innovative Veterinary Care Journal
Learn More →
Press Releases
40 Under 40 in Cancer Class of 2022 Recognizes Dr. Sungwon Lim, ImpriMed CEO & Co-Founder
EIN Presswire
Learn More →
In the News
Early leukemia and lymphoma remissions in cats and dogs
Innovative Veterinary Care Journal
Learn More →
In the News
Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)
One Million by One Million
Learn More →
In the News
Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)
One Million by One Million
Learn More →
In the News
Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)
One Million by One Million
Learn More →
In the News
Technological advancement makes cancer treatment easier
Innovative Veterinary Care Journal
Learn More →
Press Releases
ImpriMed Presents New Research Findings at The Veterinary Cancer Society (VCS) Mid-Year Conference
EIN Presswire
Learn More →
In the News
Novel veterinary oncologic treatments and diagnostics
dvm360
Learn More →
Presentations
Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma
Veterinary Cancer Society Mid-Year Conference 2022
Learn More →
Presentations
ImpriMed Research Update
Veterinary Cancer Society Mid-Year Conference 2022
Learn More →
Press Releases
ImpriMed AI and machine learning is disrupting the veterinary oncology tools available for better treatment outcomes
EIN Presswire
Learn More →
Presentations
Precision medicine for pet cancer care
Animal Health, Nutrition and Technology Innovation Europe 2022
Learn More →
Press Releases
ImpriMed Publishes Exclusive Canine Patients Data Analysis
EIN Presswire
Learn More →
In the News
AI’s Computing Power Could Make Fusion Energy Practical
Lifewire
Learn More →
Press Releases
ImpriMed CEO and Co-founder Dr. Sungwon Lim Wins Prestigious “Top Industry Leader” Award from Life Sciences Voice
EIN Presswire
Learn More →
Press Releases
ImpriMed Reports Significant Growth in 2021 with Pre-Series A Funding, New Product Launches, and Team Expansion
EIN Presswire
Learn More →
Previous
Next
